Canada Markets closed

Panbela Therapeutics, Inc. (PBLA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.76000.0000 (0.00%)
At close: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close1.7600
Open1.7495
Bid1.6900 x 800
Ask1.7700 x 1200
Day's Range1.7400 - 1.8600
52 Week Range1.7000 - 8.8000
Volume84,001
Avg. Volume51,528
Market Cap17.756M
Beta (5Y Monthly)0.19
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
  • GlobeNewswire

    Panbela Announces Acceptance of Abstract for Poster Presentation at American Society of Clinical Oncology Gastrointestinal Cancers Symposium

    MINNEAPOLIS, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced that an abstract for SBP-101, a proprietary polyamine analogue, has been accepted for poster presentation at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, which will be held January 20-22, 2022. Details of the presentation are as follo

  • GlobeNewswire

    Panbela Provides Business Update and Reports Q3 2021 Financial Results

    MINNEAPOLIS, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today provided a business update and reported financial results for the quarter ended September 30, 2021. Management is hosting an earnings call today at 4:30 p.m. ET. The third quarter 2021 was marked by further meaningful clinical progress. Recent Highlights 16 patients are in survival

  • GlobeNewswire

    Panbela Schedules Conference Call on November 10, 2021, to Report 2021 Third Quarter Financial Results

    MINNEAPOLIS , Oct. 25, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced that it will host a conference call on November 10, 2021, at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2021. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the ca